Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial

Pathologic complete response (pCR) is a predictor for favorable outcome after neoadjuvant treatment in early breast cancer. Modulation of gene expression may also provide early readouts of biological activity and prognosis, offering the possibility for timely response‐guided treatment adjustment. Th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Cancer
Autori principali: Kimbung, Siker, Markholm, Ida, Bjöhle, Judith, Lekberg, Tobias, von Wachenfeldt, Anna, Azavedo, Edward, Saracco, Ariel, Hellström, Mats, Veerla, Srinivas, Paquet, Eric, Bendahl, Pär‐Ola, Fernö, Mårten, Bergh, Jonas, Loman, Niklas, Hatschek, Thomas, Hedenfalk, Ingrid
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Tumor Markers and Signatures
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765477/
https://ncbi.nlm.nih.gov/pubmed/28940389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31070
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi